Executive summary: U.S. Patent 9,980,944 is a US method-of-treatment patent that claims a BRAF-mutant (BRAFV600-mutant) melanoma treatment workflow combining (i) detection of BRAF-mutant status and (ii) administering a specific crystallized benzimidazole carboxamide active: crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide. The claim set also captures combination therapy sequencing (simultaneous or separate dosing with broad classes of anticancer agents) and oral tablet formulations with specific excipient and ~15 mg dose limitations. The landscape inference is that enforceable scope likely concentrates on: (1) use in BRAF-mutant melanoma with v600 status; (2) use of the crystalline form of the specified compound; (3) method steps (diagnostic gating) and (4) specific oral tablet embodiments.
U.S. Patent 9,980,944 claims scope for BRAF-mutant melanoma crystalline benzimidazole carboxamide
What does US 9,980,944 claim for treating BRAF-mutant melanoma?
Core independent claim (Claim 1) is a two-step method:
- Detect melanoma in a patient that is BRAF-mutant melanoma.
- Administer a therapeutically effective amount of a pharmaceutical composition comprising the crystallized compound:
crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide.
Immediate scope implications
- The patent is diagnostic-step gated: infringing activity is tied to treating a patient after determining BRAF-mutant status.
- The active ingredient is not described generically as “the compound.” It is limited to a crystallized form of a specific chemical identity.
- “A therapeutically effective amount” is open-ended enough for routine dosing, but crystallinity and identity are hard limits.
How broad is the BRAF-mutant coverage, and where do BRAFV600 limitations appear?
- Claim 1 requires BRAF-mutant melanoma (broad category).
- Claim 2 narrows to BRAFV600-mutant melanoma (subset).
Enforcement consequences
- If accused conduct uses the compound in BRAF-non-V600 mutant melanoma, it potentially falls under Claim 1 but not Claim 2.
- If accused conduct targets V600 patients, both Claim 1 and Claim 2 are in play.
What is protected about “crystallized” active, and how does that narrow claim reach?
The composition is defined as comprising the crystallized active chemical. This introduces at least three potential narrowing handles for claim construction and noninfringement:
- Polymorph/crystal form identity: practicing the method with an amorphous or different polymorphic form could be outside the literal claim scope.
- Manufacturing-derived solid-state: crystallization conditions that yield a different form could reduce risk of literal infringement.
- “comprising” language: Claim 1 says the composition comprises the crystallized active. Excipients/additives do not avoid infringement if the crystallized active is present.
What combination therapy does claim 3 add, and how does it expand coverage?
Claim 3 adds:
- “Further comprising treating” with at least one additional therapeutic agent selected from a wide group including:
- mitotic inhibitors
- alkylating agents
- anti-metabolites
- intercalating antibiotics
- growth factor inhibitors
- cell cycle inhibitors
- enzyme inhibitors
- topoisomerase inhibitors
- biological response modifiers
- anti-hormones
- angiogenesis inhibitors
- anti-androgens
Scope expansion
- This is a broad combination clause that covers many standard oncology drug classes.
- Because the additional agent selection is categorical, the key remaining infringement gate is whether the patient is treated per the Claim 1 detection + crystallized compound administration steps.
Does the patent cover combination timing (simultaneous vs separate dosing)?
Yes:
- Claim 4: simultaneous administration of the claimed composition and the additional therapeutic agent.
- Claim 6: separate administration (timing different) of the same two components.
Coverage gap analysis
- The claim family appears designed to capture typical real-world regimens where drugs are either co-administered or staggered.
Is there a formulation-specific claim set for oral tablets?
Yes. The tail end of the claim set focuses on oral solid dosage forms:
- Claim 8: pharmaceutical composition formulated for oral administration.
- Claim 9: formulated as a tablet.
- Claim 10: tablet further comprises specific excipients:
- lactose monohydrate
- microcrystalline cellulose
- colloidal silicon dioxide
- croscarmellose sodium
- magnesium stearate
- Claim 11–12: tablet comprises approximately 15 mg of the crystallized active (Claims 11 and 12 repeat the excipient limitation context and the ~15 mg dose).
Key legal/technical implication
- Oral tablet embodiments are only directly claimed where the dosage form and excipient set match. If a competitor uses:
- a different oral form (capsule, suspension, film, ODT with different excipient set), or
- a different dose strength (not “approximately 15 mg”),
- or substitutes excipients,
it may reduce risk of Claim 9–12 literal coverage, while Claim 1–4 or Claim 3–6 method claims may remain.
What is the net “scope map” across the claim set?
Layer 1: patient population + decision step
- BRAF-mutant melanoma detection (Claim 1)
Layer 2: specific active + solid-state
- Administration of the crystallized compound (Claim 1)
Layer 3: additional therapy category
- Add-on treating with broadly defined oncology classes (Claim 3)
Layer 4: dosing sequence
- simultaneous (Claim 4) or separate (Claim 6)
Layer 5: molecular subset
- BRAFV600-mutant melanoma (Claim 2 and dependent in Claims 5 and 7)
Layer 6: dosage form and excipient tailoring
- oral (Claim 8), tablet (Claim 9), excipient-defined tablet (Claim 10), ~15 mg strength (Claims 11–12)
How strong is the patent estate likely to be around these claim elements?
What elements are hardest for generic or follow-on products to avoid?
Given the claim drafting, the hardest-to-work-around elements are:
- BRAF-mutant detection + then treating: method-of-use claims often require the medical practice itself to match the claimed steps.
- Use of the crystallized form: solid-state form identity can be a frequent differentiator in “same API, different form” strategies, but the patent explicitly requires crystallization.
- Composition administration: method claims do not require identical regimen details beyond those recited.
Where are typical design-around opportunities most available?
- Avoiding the tablet/excipient/dose limitations if only the dosage-form claims are relevant:
- switch oral dosage form
- different excipient combination
- different dose strength not “approximately 15 mg”
- Avoiding the BRAFV600 subset claims (Claims 2/5/7) by treating non-V600 BRAF mutants could evade those dependents, but Claim 1 still covers BRAF-mutant broadly.
What does the broad additional-therapy list mean for infringement risk?
Because Claim 3’s additional agent selection is extremely inclusive, a likely risk pattern is:
- if clinicians already use standard-of-care combinations that fall into those classes, the additional-agent element is easy to satisfy; the harder question becomes the underlying administration of the crystallized active and the BRAF-mutant detection gate.
Patent landscape assessment for US 9,980,944 method claims: what to look for in related patents
What claim-adjacent patent categories likely surround 9,980,944?
Even without external listing details, the claim structure signals that the broader estate (where it exists) is typically split across:
- chemical composition/polymorph patents covering the crystalline form of the benzimidazole carboxamide
- pharmaceutical composition formulation patents (tablet excipients, manufacturing, dose strengths)
- method-of-use patents for melanoma and/or BRAF-mutant subgroups
- combination regimen patents with targeted sequencing language
Practical estate mapping approach (business use)
- Track patents that claim the same:
- chemical identity
- crystal form
- oral tablet formulation
- BRAF-mutant/BRAFV600 melanoma treatment workflow
- Identify whether any separate patents claim:
- the diagnostic testing method steps (some estates add independent diagnostic claims)
- the combination drug pairings with specific agents rather than generic class language
How many claim “entry points” create licensing leverage?
This claim family has multiple independent leverage points:
- the basic method-of-treatment step (Claim 1)
- the narrow v600 subset (Claim 2)
- combination simultaneous vs separate (Claims 4 and 6)
- dosage form claims (Claims 8–12)
A licensing strategy typically targets the most commercially relevant embodiment:
- if the marketed product is an oral tablet at ~15 mg with those excipients, the formulation claims increase leverage
- if the clinical program uses BRAF-mutant detection and the crystalline active as part of routine regimens, the method claims increase leverage
Orange Book status: what matters for method claims like 9,980,944?
What is the relevance of Orange Book listings to 9,980,944-style method claims?
Orange Book listings generally attach to FDA-approved drug products and their active ingredients and patents. For method-of-use patents:
- they may be listed in the Orange Book if tied to an approved indication or dosage form.
- the practical effect for generic entry hinges on whether a generic can certify against the listed patent(s) and how the patent is interpreted relative to the generic’s labeling and product.
Business implication
- If 9,980,944 (or related patents) is Orange Book-listed for the relevant indication, Paragraph IV strategy risk increases for generics planning that indication and regimen.
When does exclusivity expire relative to 9,980,944?
How to think about timing for a method-of-use patent?
A method-of-use patent’s enforceability persists until:
- the patent expires (utility term), or
- earlier if a terminal disclaimer cuts the term, or
- if invalidated in litigation.
Commercial timing sensitivity
- If the compound has multiple “layers” of patenting (crystal form, composition, formulation, method), exclusivity effectively requires clearing the last-to-expire relevant patent in that chain, not just the earliest.
What generic entry risks exist for BRAF-mutant melanoma if 9,980,944 is asserted?
What would a generic need to do to avoid infringing the method claims?
In practice, avoiding infringement depends on whether the generic is:
- providing the claimed crystallized active (solid-state)
- labeled and administered for BRAF-mutant melanoma using detection gating
- used with combination regimens in ways that satisfy Claim 3 and timing limits
Generic risk tends to spike when:
- generic labeling includes the patented indication
- physicians practice the claimed detection + treatment workflow
- the generic product matches the claimed crystalline form and dose/form factor used clinically
Does changing formulation avoid method-of-use infringement?
Not necessarily. Even if a generic uses different excipients or a different oral device, method claims can still be implicated if the generic product administers the claimed crystallized active and is used for BRAF-mutant melanoma per the claimed steps.
Formulation changes mainly mitigate dependent claims tied to tablet excipients and dose (Claims 8–12), not necessarily the core method-of-treatment claim (Claim 1).
How would litigation likely frame claim construction for this patent?
Key disputed claim construction terms
- “BRAF-mutant melanoma” and “BRAFV600-mutant melanoma”
- “detecting” (what diagnostic modality qualifies and when detection must occur)
- “crystallized” (what is required to prove the solid-state form)
- “pharmaceutical composition comprising” (what counts as “comprising” in product composition evidence)
- “approximately 15 mg” (dose range interpretation)
- excipients list matching for the tablet limitations
Evidence likely used
- clinical practice protocols showing BRAF testing prior to therapy
- product composition and solid-state characterization (XRPD, DSC, Raman, solid-state NMR)
- tablet formulation specs showing excipients and strength
Key Takeaways
- U.S. Patent 9,980,944 is centered on a method-of-treatment for BRAF-mutant melanoma with a diagnostic detection step followed by administering a crystallized benzimidazole carboxamide.
- The scope expands through:
- BRAFV600 subset dependents
- broad combination therapy classes with both simultaneous and separate dosing dependents
- oral tablet dependents with a specific excipient set and ~15 mg strength limitations.
- The highest-risk infringement vectors are:
- clinical workflows that test for BRAF mutation and then treat with the crystallized active
- products that match the crystal form and are administered as in-field.
- Dosage-form design-around is more credible for narrowing Claims 9–12 than for avoiding Claim 1’s core method coverage.
FAQs
- Can a product that uses the same chemical but a different crystal form avoid infringement of 9,980,944?
- Does 9,980,944 require the patient to be BRAF-tested before dosing, or is it enough that the tumor is BRAF-mutant?
- If a clinician treats BRAFV600-mutant melanoma without a specific diagnostic “detection step,” does the method still infringe?
- If a competitor markets a different tablet strength than ~15 mg, does that avoid the dependent formulation claims?
- How do combination regimen choices affect whether Claims 3, 4, and 6 are met?
References
(No references provided in the prompt.)
